MARKET WIRE NEWS

Rapport Therapeutics Inc. (NASDAQ : RAPP ) Stock

Share:

MWN-AI** Summary

MWN-AI** Analysis

**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.


Description


Rapport Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.


Quote


Last:$29.84
Change Percent: 4.37%
Open:$29.35
Close:$28.59
High:$30.08
Low:$29.09
Volume:28,109
Last Trade Date Time:02/27/2026 12:26:38 pm

Stock Data


Market Cap:$1,346,118,602
Float:30,701,034
Insiders Ownership:0.05%
Institutions:34
Short Percent:N/A
Industry:Biotechnology & Life Sciences
Sector:Healthcare
Website:https://www.rapportrx.com
Country:US
City:Boston

Recent News Releases


Subscribe to Our Newsletter


Message Board Posts


**MWN-AI FAQ is based on asking OpenAI questions about Rapport Therapeutics Inc. (NASDAQ: RAPP).

Link Market Wire News to Your X Account

Download The Market Wire News App